,63 Since recombinant soluble angiotensin-converting enzyme 2 (rsACE2) protein can competitively inhibit SARS-CoV-2 binding to ACE2-expressing cells in vitro and block infection,64 EVs harboring ACE2 represent a potential therapeutic strategy to limit viral infection progression in vivo.62 The gene discussed is ACE2; the disease is infection.